Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects
The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before…
Rockland Launches Impurity Detection Kit for Accurate Measurement of Nuclease Across a Spectrum of Therapeutic Manufacturing Methods
For over 60 years, Rockland has been providing antibodies, assays, and supporting reagents to accurately reflect the quality of biopharmaceutical products from early- to late-stage bioprocessing. Rockland is a leading expert in antibody and immunoassay development, delivering high coverage and sensitivity against residual contaminants…
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next generation…
Trio Health Appoints Dr. Mia Nease as Chief Commercial Officer
Trio Health (Trio), a leading clinical data solution provider, has announced the appointment of Mia Nease as its Chief Commercial Officer (CCO). In this role, Nease will lead the advancement of Trio’s commercialization strategy and oversee the development of innovative solutions to…
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics, a leading CDMO that enables its partners’ success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage biotech company, announced on September 28 that the companies are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115. Under…
Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM
Veeva Systems (NYSE: VEEV) today announced that 17 of the top 20 biopharmas in Asia Pacific are using Veeva CRM for more effective engagement with healthcare professionals (HCPs). Companies like Boehringer Ingelheim and MSD use Veeva CRM to gain greater…
